Tissue-Based Research in Kidney Cancer: Current Challenges and Future Directions
暂无分享,去创建一个
F. Waldman | C. Compton | J. Gillespie | T. Libermann | J. Haaga | W. Linehan | S. Signoretti | V. Reuter | M. Atkins | M. Merino | G. Bratslavsky | G. Thomas | M. Pins | J. Tomaszewski | Andrew Hruszkewycz
[1] S. Signoretti,et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. , 2007, Clinical genitourinary cancer.
[2] Michael A S Jewett,et al. Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. , 2007, The Journal of urology.
[3] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[4] S. Signoretti,et al. The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer , 2007, Clinical Cancer Research.
[5] T. Libermann,et al. Genomics of Renal Cell Cancer: The Biology Behind and the Therapy Ahead , 2007, Clinical Cancer Research.
[6] Mark A Rosen,et al. Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference , 2007, Clinical Cancer Research.
[7] James Brugarolas,et al. Renal-cell carcinoma--molecular pathways and therapies. , 2007, The New England journal of medicine.
[8] R. Motzer,et al. Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma , 2006, Clinical Cancer Research.
[9] R. Motzer,et al. Novel targets and therapies for metastatic renal cell carcinoma. , 2006, Oncology.
[10] V. Kaklamani,et al. A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX , 2006, Expert review of molecular diagnostics.
[11] Victor E Reuter,et al. The pathology of renal epithelial neoplasms. , 2006, Seminars in oncology.
[12] K. Chew,et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel‐Lindau gene status , 2006, BJU international.
[13] T. Hampton. Trials probe new agents for kidney cancer. , 2006, JAMA.
[14] Antonio Lopez-Beltran,et al. 2004 WHO classification of the renal tumors of the adults. , 2006, European urology.
[15] A. Hanlon,et al. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. , 2006, The Journal of urology.
[16] F. Pontén,et al. Biobanking of fresh frozen tissue: RNA is stable in nonfixed surgical specimens , 2006, Laboratory Investigation.
[17] I. Mellinghoff,et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer , 2006, Nature Medicine.
[18] Marie Joseph,et al. Gene Signatures of Progression and Metastasis in Renal Cell Cancer , 2005, Clinical Cancer Research.
[19] S. Signoretti,et al. Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer , 2005, Clinical Cancer Research.
[20] J. Giltnane,et al. Technology Insight: identification of biomarkers with tissue microarray technology , 2004, Nature Clinical Practice Oncology.
[21] D. Rimm,et al. Long-term preservation of antigenicity on tissue microarrays , 2004, Laboratory Investigation.
[22] F. Erdoğan,et al. Prognostic significance of morphologic parameters in renal cell carcinoma , 2004, International journal of clinical practice.
[23] F. Rybicki,et al. Percutaneous biopsy of renal masses: sensitivity and negative predictive value stratified by clinical setting and size of masses. , 2003, AJR. American journal of roentgenology.
[24] D. Rimm,et al. Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.
[25] D. Rossi,et al. Fine-needle percutaneous biopsy of renal masses with helical CT guidance. , 2000, Radiology.
[26] S. Fuhrman,et al. Prognostic significance of morphologic parameters in renal cell carcinoma , 1982, The American journal of surgical pathology.
[27] M. Karno,et al. Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.